Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 9/20 | 0.56 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018414 | 1.00 | LSS (0.56) | LSSACHEADAMTS4MMP8ADAMTS5 | |
| SCHEMBL6019097 | 1.00 | LSS (0.56) | LSSACHEADAMTS4MMP8ADAMTS5 | |
| SCHEMBL6019101 | 1.00 | LSS (0.56) | LSSACHEADAMTS4MMP8ADAMTS5 | |
| SCHEMBL6019160 | 0.94 | LSS (0.56) | LSSACHEADAMTS4MMP8ADAMTS5 | |
| SCHEMBL6019024 | 0.94 | LSS (0.56) | LSSACHEADAMTS4MMP8ADAMTS5 | |
| SCHEMBL6019164 | 0.94 | LSS (0.56) | LSSACHEADAMTS4MMP8ADAMTS5 | |
| SCHEMBL6019017 | 0.94 | LSS (0.56) | LSSACHEADAMTS4MMP8ADAMTS5 | |
| SCHEMBL6018667 | 0.86 | LSS (0.60) | LSSACHEMEN1KMT2A | |
| SCHEMBL6018663 | 0.86 | LSS (0.60) | LSSACHEMEN1KMT2A | |
| SCHEMBL6018985 | 0.84 | LSS (0.62) | LSSACHEADAMTS4MMP8ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456171-B1 | SUBSTITUTED CYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-12-20 | — | — | EP | disclosed |
| US-20050272774-A1 | Substituted cyclohexane derivatives | ACKERMANN JEAN | 2005-12-08 | — | — | US | disclosed |
| US-6953806-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20030199550-A1 | Substituted cyclohexane derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272774-A1 | Substituted cyclohexane derivatives | LSS, CYP51A1, CYP8B1 | LSS 1/4885ACHE 1484/4885ADAMTS4 4280/4885 |
| US-20030199550-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | LSS 2/4885ACHE 2571/4885ADAMTS4 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.